Internal Lab Buildout Strategy
Pharma
25
4
14
Voice-of-Customer Research
Due Diligence
Objective
A large pharmaceutical company engaged DeciBio to evaluate strategies for an internal build of a lab to support clinical and commercial opportunities in oncology
Our Approach
Secondary Research
- Conducted analysis of key technologies and platforms to understand potential use cases and fit for client needs in the lab build
- Evaluated the tangible and intangible value of an internal lab and trade-offs between internal build vs. outsourcing
Primary Research
- Conducted 25 telephone interviews with, lab directors, and technology KOLs to gather insights on platform / workflow requirements and evolving landscape (e.g., regulatory)
- Conducted 14 internal interviews to determine internal hypotheses, anticipated sample volumes and associated costs
Quantitative Analysis
- Built a comprehensive financial model, including CapEx / OpEx to calculate the breakeven time frame using sample volume projections
- Determined NPV under various model scenarios
Outcome
DeciBio delivered a presentation to the leadership team, key takeaways included:
- Recommendation for an internal build based on cost savings and additional intangible benefits
- Evaluation of associated risks of build
- Determined lab design configurations and built roadmap (e.g., personnel requirements, CLIA/CAP, instruments, layout etc.)
Related Client Results

PE-Backed Life Sciences Tools Platform Development
Voice-of-Customer Research
Customer Segmentation
Pricing Strategy
Due Diligence
Competitive Analysis

Cell and Gene Therapy Services Landscape Assessment
No items found.

Global Companion Diagnostic Guideline Mapping and Strategy
Biomarker and Diagnostics Strategy
Go-to-Market Strategy



